The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross‐national descriptive study from the PROTECT‐EU Project
Open accessAbstract
Purpose: Studies on drug utilization usually do not allow direct cross‐national comparisons because of differences in the respective applied methods. This study aimed to compare time trends in BZDs prescribing by applying a common protocol and analyses plan in seven European electronic healthcare databases. Methods: Crude and standardized prevalence rates of drug prescribing from 2001–2009 were calculated in databases from Spain, United Kingdon (UK), The Netherlands, Germany and Denmark. Prevalence was stratified by age, sex, BZD type [(using ATC codes), i.e. BZD‐anxiolytics BZD‐hypnotics, BZD‐related drugs and clomethiazole], indication and number of prescription. Results: Crude prevalence rates of BZDs prescribing ranged from 570 to 1700 per 10 000 person‐years over the study period. Standardization by age and sex did not substantially change the differences. Standardized prevalence rates increased in the Spanish (+13%) and UK databases (+2% and +8%) over the study period, while they decreased in the Dutch databases (−4% and −22%), the German (−12%) and Danish (−26%) database. Prevalence of anxiolytics outweighed that of hypnotics in the Spanish, Dutch and Bavarian databases, but the reverse was shown in the UK and Danish databases. Prevalence rates consistently increased with age and were two‐fold higher in women than in men in all databases. A median of 18% of users received 10 or more prescriptions in 2008. Conclusion: Although similar methods were applied, the prevalence of BZD prescribing varied considerably across different populations. Clinical factors related to BZDs and characteristics of the databases may explain these differences. Copyright © 2015 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean, J. R., & Beers, M. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2716 · Cited by 2,389
Jansson-Fröjmark, M., & Lindblom, K. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.016 · Cited by 646
Ohayon, M. M., & Lader, M. H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0912 · Cited by 271
the ESEMeD/MHEDEA 2000 Investigators, ten Have, M., de Graaf, R., Ormel, J., Vilagut, G., Kovess, V., & Alonso, J. (2010) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-009-0050-4 · Cited by 266
A three-country comparison of psychotropic medication prevalence in youth
Zito, J. M., Safer, D. J., Berg, L. T. D. J.-V. D., Janhsen, K., Fegert, J. M., Gardner, J. F., Glaeske, G., & Valluri, S. C. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-26 · Cited by 201
Linden, M., Lecrubier, Y., Bellantuono, C., Benkert, O., Kisely, S., & Simon, G. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00007 · Cited by 133 · cited 2×
“5,6,9,26,28,29 Age ranges and study period also varied largely among studies.”
Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132 · cited 1×
“5,6,9,27,29,31,32 Our study shows that standardized prevalence rates remained rather stable over the study period in three databases (CPRD, THIN and Mondriaan-AHC), decreased in three (Mondriaan-NPCRD, Bavarian and DKMA) and increased in one (BIFAP).”
Comparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98
Are prescribed medications effective in the treatment of insomnia complaints?
Ohayon, M. M., Caulet, M., Arbus, L., Billard, M., Coquerel, A., Guieu, J.-D., Kullmann, B., Laffont, F., Lemoine, P., Paty, J., et al. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00079-8 · Cited by 70
Cited by
Langan, S. M., Schmidt, S. A., Wing, K., Ehrenstein, V., Nicholls, S. G., Filion, K. B., Klungel, O., Petersen, I., Sorensen, H. T., Dixon, W. G., et al. (2018) · BMJ · doi:10.1136/bmj.k3532 · Cited by 550
Self-citationKroll, D. S., Nieva, H. R., Barsky, A. J., & Linder, J. A. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3740-0 · Cited by 94
“51) Completed high school/GED 96 (20) 1585 (17) 1.”
BackgroundInfluentialAiding sleep in type 2 diabetes: therapeutic considerations
Tan, X., van Egmond, L., Chapman, C. D., Cedernaes, J., & Benedict, C. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30233-4 · Cited by 72
Torres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Bronskill, S. E., Campitelli, M. A., Iaboni, A., Herrmann, N., Guan, J., Maclagan, L. C., Watt, J., Rochon, P. A., Morris, A. M., Jeffs, L., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15519 · Cited by 54
Metadata
- Authors
- Huerta, C., Abbing‐Karahagopian, V., Requena, G., Oliva, B., Alvarez, Y., Gardarsdottir, H., Miret, M., Schneider, C., Gil, M., Souverein, P. C., De Bruin, M. L., Slattery, J., De Groot, M. C. H., Hesse, U., Rottenkolber, M., Schmiedl, S., Montero, D., Bate, A., Ruigomez, A., García‐Rodríguez, L. A., Johansson, S., de Vries, F., Schlienger, R. G., Reynolds, R. F., Klungel, O. H., & de Abajo, F. J.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2015-07-07
- Volume
- 25
- Issue
- S1
- Pages
- 56-65
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2134071469
- Cited by
- 130
- References
- 9
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.